Drug Profile
Research programme: anti-viral therapeutics - Globavir
Alternative Names: GBV 001; GBV-012; GBV-015Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Stanford University School of Medicine
- Developer Globavir Biosciences
- Class
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chikungunya virus infections; Dengue; Ebola virus infections; Hantavirus infections; Hepatitis B; Human papillomavirus infections; Lassa fever; Marburg virus disease; West Nile virus infections
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Dengue in USA
- 28 Sep 2018 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA
- 28 Sep 2018 No recent reports of development identified for preclinical development in Hepatitis-B in USA